Deutsche Bank
GALT icon

Deutsche Bank’s Galectin Therapeutics GALT Stock Holding History

Deutsche Bank’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Buy
+47,403
New +$123K ﹤0.01% 3201
2021
Q2 		– Sell
-25,416
Closed -$55K – 4674
2021
Q1 		$55K Sell
25,416
-2,262
-8% -$5.07K ﹤0.01% 4210
2020
Q4 		$62K Buy
27,678
+7,474
+37% +$19.6K ﹤0.01% 4060
2020
Q3 		$54K Buy
20,204
+1,796
+10% +$5.03K ﹤0.01% 3852
2020
Q2 		$56K Buy
18,408
+4,582
+33% +$11.5K ﹤0.01% 3759
2020
Q1 		$28K Sell
13,826
-7,464
-35% -$18.2K ﹤0.01% 3801
2019
Q4 		$60K Buy
21,290
+9,406
+79% +$32.7K ﹤0.01% 3881
2019
Q3 		$42K Sell
11,884
-18,290
-61% -$66.1K ﹤0.01% 4023
2019
Q2 		$124K Sell
30,174
-30,580
-50% -$132K ﹤0.01% 4094
2019
Q1 		$309K Buy
+60,754
New +$292K ﹤0.01% 3739
2018
Q3 		– Sell
-1,300
Closed -$8K – 5418
2018
Q2 		$8K Sell
1,300
-1,300
-50% -$6.33K ﹤0.01% 5187
2018
Q1 		$12K Buy
2,600
+2,598
+129,900% +$12.1K ﹤0.01% 5092
2017
Q4 		$0 Hold
2
– – ﹤0.01% 5034
2017
Q3 		$0 Sell
2
-100
-98% -$198 ﹤0.01% 4947
2017
Q2 		$0 Buy
102
+100
+5,000% +$266 ﹤0.01% 4997
2017
Q1 		$0 Hold
2
– – ﹤0.01% 4971
2016
Q4 		$0 Hold
2
– – ﹤0.01% 4962
2016
Q3 		$0 Sell
2
-11
-85% -$20 ﹤0.01% 5014
2016
Q2 		$0 Sell
13
-1,498
-99% -$2.2K ﹤0.01% 5232
2016
Q1 		$2K Sell
1,511
-3,975
-72% -$5.34K ﹤0.01% 5045
2015
Q4 		$8K Buy
5,486
+3,986
+266% +$9.13K ﹤0.01% 4970
2015
Q3 		$3K Sell
1,500
-1,958
-57% -$4.62K ﹤0.01% 5083
2015
Q2 		$9K Buy
3,458
+867
+33% +$2.61K ﹤0.01% 5064
2015
Q1 		$8K Sell
2,591
-28,919
-92% -$103K ﹤0.01% 4826
2014
Q4 		$109K Sell
31,510
-163
-0.5% -$720 ﹤0.01% 4674
2014
Q3 		$158K Buy
31,673
+86
+0.3% +$670 ﹤0.01% 4221
2014
Q2 		$435K Buy
31,587
+28,441
+904% +$354K ﹤0.01% 3573
2014
Q1 		$48K Buy
+3,146
New +$44.8K ﹤0.01% 4566

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Deutsche Bank's GALT Position: Q2 2026 in Review

Deutsche Bank opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 47,403 shares worth $220K. The stake represents ﹤0.01% of the portfolio and ranks #3201 among its holdings. This is a return to the name: Deutsche Bank previously reported a position in GALT as recently as Q1 2021.

Deutsche Bank first reported a position in GALT in Q1 2014 and has held it in 28 quarters since. The position peaked at $435K in Q2 2014. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Deutsche Bank held 47,403 shares of Galectin Therapeutics worth $220K as of Q2 2026.
  • Galectin Therapeutics was a new Deutsche Bank position in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3201 holding.
  • Deutsche Bank first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 28 quarters since.
  • Deutsche Bank's Galectin Therapeutics position peaked at $435K in Q2 2014.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.